Atara Biotherapeutics has secured approval from the US Food and Drug Administration (FDA) to begin two Phase lll clinical trials of tabelecleucel to treat patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

One of the new global, multicentre, open-label studies will include patients with EBV+PTLD following allogeneic hematopoietic cell transplant (HCT) after the failure of rituximab (MATCH).

The other study will be carried out to treat patients with EBV+PTLD following solid organ transplant (SOT) after the failure of rituximab or rituximab plus chemotherapy (ALLELE).

Both studies are expected to be immediately opened for enrolment in the US and will later be expanded to include sites in the EU, Canada, and Australia.

Atara aims to publish results from the first tabelecleucel study in the first half of 2019.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Both protocols from the study are designed to discard 20% ORR as the null hypothesis.”

During the first half of 2019, the company also plans to submit a tabelecleucel conditional marketing authorisation (CMA) application in the EU for patients with rituximab-refractory EBV+PTLD following HCT.

Atara further plans to continue working with the FDA, Health Canada and other global health authorities to make tabelecleucel available to patients as early as possible.

The primary endpoint for both trials is to achieve the confirmed objective response rate (ORR), defined as the percent of patients achieving either a complete or partial response to tabelecleucel treatment confirmed after the initial tumour assessment showing a response.

Both protocols from the study are designed to discard 20% ORR as the null hypothesis.

Secondary endpoints of the MATCH and ALLELE studies will comprise the duration of response, overall survival, safety, quality of life metrics, as well as other data in support of potential health economic benefits.